updated overall survival data on eltanexor for hma-refractory mds
Published 3 years ago • 102 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
1:57
combining molecular and clinical data to predict survival & transformation risk in patients with mds
-
1:15
overall survival data from the pollux trial: drd versus rd in patients with r/r multiple myeloma
-
1:06
the prognostic value of self-reported fatigue on overall survival in patients with mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:23
the current landscape of treatment for hr-mds: an update from ash 2023
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
1:04
long-term survival outcomes in pts with mf treated with momelotinib vs danazol in the momentum trial
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
1:13
challenges in risk stratifying lr-mds: insights into genetic upstaging and early transplant
-
1:02
emerging treatment options for lower- and higher-risk mds and ongoing trials
-
1:06
derive trial update: did vs dvd in newly diagnosed mm
-
2:35
methods of optimizing transplantation in mds
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
2:07
the clearance of driver mutations following allosct impacts myelofibrosis disease outcomes
-
4:48
the evolution of allosct in richter's transformation and its combination with biological agents
-
3:37
progress in the categorization and treatment of lr-mds